Trial Profile
A Phase 1b Trial of the IRX-2 Regimen and Nivolumab in Patients With Advanced Hepatocellular Cancer (HCC)
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 05 Feb 2024
Price :
$35
*
At a glance
- Drugs Cyclophosphamide (Primary) ; IRX 2 (Primary) ; Nivolumab (Primary)
- Indications Liver cancer
- Focus Adverse reactions
- 29 Jan 2024 Planned End Date changed from 15 Dec 2023 to 15 Dec 2024.
- 29 Jan 2024 Planned primary completion date changed from 15 Dec 2023 to 15 Dec 2024.
- 03 Jul 2023 Planned End Date changed from 15 Jun 2023 to 15 Dec 2023.